Details of the Drug Reposition

General Information of This Drug (ID: DMXLKHV)

Drug Name
Oxycodone   DMXLKHV
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Osteoarthritis DIS05URM FA00-FA05 Approved [1]
Pain DIS4RWOW MG30-MG3Z Approved [2]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Back pain DISDSMNI ME84.Z Phase 3 [3]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Constipation DISRQXWI DD91.1 Discontinued in Phase 3 [4]
------------------------------------------------------------------------------------

References

1 Oxycodone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093).
3 ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health.
4 ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, nave to Anti-VHB Therapy